Biomedical Research and Therapy <p><strong>Biomedical Research and Therapy</strong> publishes 12 peer-reviewed issues per year in all fields of biomedical and clinical sciences for internationally diverse authorship. Unlike most open access journals, which are free to readers but not authors, Biomedical Research and Therapy does not charge for subscription, submission, processing, or publication of manuscripts, nor for color reproduction of photographs. An international peer-reviewed journal, it publishes high quality open access research articles with a special emphasis on basic, translational and clinical research into molecular therapeutics and cellular therapies, including animal models and clinical trials. The peer-review process will only accept content that is scientifically, technically and ethically sound, and in compliance with standard reporting guidelines. Biomedical Research and Therapy's Editorial Policies follow the recommendations of the <a href="" target="_blank" rel="noopener">International Committee of Medical Journal Editors (ICMJE)</a>, <a href="" target="_blank" rel="noopener">the World Association of Medical Editors (WAME)</a>, and&nbsp;<a href="" target="_blank" rel="noopener">the Committee on Publication Ethics (COPE)</a> for guidance on policies and procedures related to publication ethics.</p> <p>The journal is indexed and abstracted by <strong><a href=";ISSN=2198-4093" target="_blank" rel="noopener">ESCI&nbsp; </a></strong>(Web of Science, Clarivate Analytics). Journal Citation Indicator (2020):<strong> <a href=";ISSN=2198-4093" target="_blank" rel="noopener">0.16</a></strong></p> Biomedpress en-US Biomedical Research and Therapy 2198-4093 <p>Copyright The Author(s) 2017. This article is published with open access by <a href="" target="_blank">BioMedPress</a>. This article is distributed under the terms of the&nbsp;<a href="" target="_blank">Creative Commons Attribution License (CC-BY 4.0)</a> which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.&nbsp;</p> Unlocking effective transgene expression potential in gene therapy with viral vectors <p>Gene therapy is an experimental approach for treating or preventing disease by using genes. Due to its promised therapeutic benefits for various diseases, this technology has drawn much interest in recent years. Despite reports of adverse events caused by gene therapies, success stories have increasingly emerged. The key to the success of gene therapy is finding a suitable DNA vector that will transport the gene into host cells, thus leading to the expression of the desired protein. An effective vector must be very efficient in delivering a gene to the target cells, non-toxic and safe to patients, inexpensive, and simple to use. This review discusses various aspects of the viral vectors currently in use in gene delivery systems and their great potential to unlock effective transgene expression in gene therapy applications based on this platform.</p> Nur Shuhaidatul Sarmiza Abdul Halim Noor Hanis Abu Halim Lelamekala Vengidasan Norashikin Zakaria Ida Shazrina Ismail Badrul Hisham Yahaya ##submission.copyrightStatement## 2021-10-06 2021-10-06 8 10 4596 4611 10.15419/bmrat.v8i10.695 title description none g Significance of Sialoglycans in SARS-CoV2 Infection <p>The second wave of coronavirus disease 19 (COVID-19) has hit India badly with a rapid surge of cases. One of the greatest challenges in managing infections from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the incomplete knowledge regarding the disease course, hypersensitivity, and relative resistance in a number of individuals. Recently, it has been reported that besides the Angiotensin-converting enzyme 2 (ACE2), certain sialic acids present on the cell surface may also function as potential receptors for binding the spike protein of SARS-CoV-2. In this brief commentary we briefly discuss the role of sialic acids in SARS-CoV-2 infection and suggest more research investigations pertaining to this arena. This may pave the way for breakthrough solutions to combat the current pandemic more effectively by developing specific drug-targeted therapies.</p> Saravanakarthikeyan Balasubramanian Divya Vinayachandran ##submission.copyrightStatement## 2021-10-09 2021-10-09 8 10 4612 4613 10.15419/bmrat.v8i10.696 title description none g Case Report on Adjunct Intravenous Autologous Activated Platelet-Rich Plasma Therapy in Severely Ill COVID-19 Patients <p>In most people, COVID-19 presents as a mild disease. However, in many people, especially those with comorbidities, profound inflammation manifesting as a cytokine storm may lead to acute respiratory distress syndrome and multi-organ failure. This novel study reports two severe COVID-19 patients from Koja Regional Hospital: a male aged 52 and a female aged 65. Both patients had poor prognoses based on prognostic biomarkers, disseminated intravascular coagulation, nosocomial infections, and were reintubated more than once. Both patients were treated with adjunct autologous activated platelet-rich plasma — a safe and promising therapy — and were ultimately discharged. Thus, this study reports the potential of autologous activated platelet-rich plasma as supportive therapy for severe COVID-19 patients.</p> Karina Karina Louis Martin Christoffel Rita Novariani Imam Rosadi Iis Rosliana Siti Rosidah Siti Sobariah Novy Fatkhurohman Nurlaela Puspitaningrum Yuli Hertati Irsyah Afini Difky Ernanda Tias Widyastuti Sulaeha AD Alfida Zakiyah Noor Aini Hubert Andrew ##submission.copyrightStatement## 2021-10-17 2021-10-17 8 10 4614 4619 10.15419/bmrat.v8i10.697 title description none g